CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- 4 Planned sale CMO & Head of Development sold 3,611 shares at $15.02 ($54,220)
- 4 Planned sale CEO and President sold 7,100 shares at an average $16.02 ($113,728)
- 4 Planned sale Chief Scientific Officer sold 8,124 shares at an average $16.02 ($130,164)
- 4 Planned sale Chief Scientific Officer sold 100 shares at $16.00 ($1,600)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale CEO and President sold 400 shares at $16.00 ($6,400)
- 4 Planned sale Chief Scientific Officer sold 400 shares at $16.00 ($6,400)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Chief Scientific Officer sold 4,170 shares at an average $14.94 ($62,305)
- 144 Insider Sale of Securities
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale CMO & Head of Development sold 3,611 shares at an average $14.18 ($51,188)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 8-K Event Executive or director change
Page 4 of 11 · 202 filings